Eli Lilly is set to acquire Centessa Pharmaceuticals for approximately $6.3 billion, a strategy aimed at enhancing its pipeline with advanced orexin receptor 2 agonists addressing neurological disorders. This acquisition will provide access to Centessa's innovative drug candidates, including those currently in Phase II trials, while aligning with Lilly's commitment to transformative treatment options. Centessa, recently valued at $1.72 billion, continues its development of medicines designed to improve patient lives, solidifying its role in the expanding neuroscience therapeutics market.
“Centessa Pharmaceuticals · is pursuing · Orexin Receptor 2 Agonist Program · potentially transformative treatment options”
“Centessa Pharmaceuticals · is · a clinical-stage pharmaceutical company · true”
“Centessa Pharmaceuticals · aims to discover and develop · medicines that are transformational for patients · true”
“Centessa Pharmaceuticals · is developing · potential best-in-class orexin receptor 2 (OX2R) agonists · true”
“Centessa Pharmaceuticals · anticipates that its orexin agonists may have utility in treating · impaired attention, cognitive deficits, fatigue and other symptoms · true”
“Centessa Pharmaceuticals · includes · its proprietary LockBody® technology platform in its earlier stage pipeline · true”
“Centessa Pharmaceuticals · is to participate in · upcoming investor conferences · true”
“Centessa Pharmaceuticals PLC ADR · is traded on · Nasdaq · CNTAU.S.”
“Centessa Pharmaceuticals PLC ADR · has a last updated price · 39.39 · USD”
“Centessa Pharmaceuticals PLC ADR · has an after-hours volume · 123.03K”
“Centessa Pharmaceuticals PLC ADR · has a daily range · 39.53 - 39.62 · USD”
“Centessa Pharmaceuticals PLC ADR · has a 52-week range · 10.95 - 40.26 · USD”
